Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 26Rectal Neoplasms 8Colonic Neoplasms 8Stomach Neoplasms 2Pancreatic Neoplasms 1Metastatic Gastric Adenocarcinoma 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Bile Duct Neoplasms 1Advanced Gastric Cancer 1

Interventions

Gemcitabine 24Cisplatin 14Capecitabine 12Oxaliplatin 11Fluorouracil 11Leucovorin 7Irinotecan 7Radiotherapy 5durvalumab 4Photochemotherapy 3Magnetic Resonance Spectroscopy 3Long-Term Synaptic Depression 3Erlotinib Hydrochloride 3Cholangiopancreatography, Endoscopic Retrograde 3Carboplatin 3trifluridine tipiracil drug combination 2regorafenib 2olaparib 2ceralasertib 2Stents 2Sorafenib 2Radiosurgery 2Radiofrequency Ablation 2Liver Transplantation 2Filgrastim 2Dihematoporphyrin Ether 21-phenyl-3,3-dimethyltriazene 2zimberelimab 1tivozanib 1titanium silicide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bile Duct Neoplasms × Trifluridine × Clear all
NCT04072445 2023-08-09

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Mayo Clinic

Phase 2 Completed
28 enrolled 20 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡